口服抗凝药物临床治疗研究进展

Advances in clinical studies of oral anticoagulation

目的:每年有近90万的人群受某种程度的静脉血栓影响,临床常用的传统口服抗凝药物如华法林等,由于剂量调整复杂、不良反应较多、药物间相互作用普遍导致使用受到一定影响。而随着对凝血机制的深入研究,基于新靶点的抗凝药物相继被研发上市,如通过美国FDA批准的达比加群酯和利伐沙班等。关于口服抗凝药疗效与安全性的临床研究一直都是热点问题。方法:本文对近期发表的各类抗凝药物治疗进展进行综述,纳入相关临床研究。结果:纳入包括传统口服抗凝药和新型口服抗凝药在内的多种药物的相关临床治疗研究。结论:随着更多抗凝药物研究进一步开展,人们对口服抗凝药的疗效及潜在风险会有越来越多的认识。

Objective：Approximately 900 000 people are affected by some sort of venous thromboembolic event every year.The traditional oral anticoagulation used commonly in clinic is warfarin,which is used restrictedly because of the dosing complexity,adverse reactions and the drug-drug interactions.With the development of clotting mechanism,anticoagulant drugs based on new targets are overwhelming.So far,there are dabigatran etexilate and rivaroxaban on the market approved by the U.S.FDA.The studies about the effectiveness and safety of oral anticoagulant drugs have always been the research hotspot.Methods：Clinical trials about the effectiveness and safety of oral anticoagulation are being made.The major clinical studies published recently were reviewed in this article.Results：Clinical studies involving traditional oral anticoagulants and new oral anticoagulants were included.Conclusion：With the increasing number of researches on anticoagulation,we can have better understanding about the effectiveness and potential risk of oral anticoagulation.